Carbonyl reduction pathways in drug metabolism

@article{Maltkov2014CarbonylRP,
  title={Carbonyl reduction pathways in drug metabolism},
  author={Petra Mal{\'a}tkov{\'a} and Vladim{\'i}r Ws{\'o}l},
  journal={Drug Metabolism Reviews},
  year={2014},
  volume={46},
  pages={123 - 96}
}
Abstract The understanding of drug biotransformation is an important medical topic. The oxidative pathways that involve CYPs have been extensively studied in drug metabolism in contrast to the reductive pathways. This review focuses on drugs that have been reported to be reduced at the carbonyl group in vivo. Although the carbonyl reduction of these drugs is well known, our understanding of the carbonyl reducing enzymes (CRE) that perform these reactions is limited. We have summarized the… Expand
The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
TLDR
The reductive metabolism of oxcarbazepine was shown to occur largely in the liver cytosol rather than liver microsomes, and the activity and stereospecificity of cytosolic carbonyl reducing enzymes toward oxcarbzepine were assessed. Expand
The role of carbonyl reductase 1 in drug discovery and development
TLDR
The CBR1 enzyme is covered in detail including discussion on topics such as tissue distribution, species difference, individual variability, the effect of genetic polymorphism and disease state, inducibility and drug-drug interaction potential. Expand
The modulation of carbonyl reductase 1 by polyphenols
TLDR
In vivo studies would be very helpful for the evaluation of risks/benefits of polyphenol interactions with CBR1, which plays an important role in drug metabolism as well as in the protection of the organism against potentially harmful carbonyls. Expand
Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics
TLDR
This series of articles provides additional support for the role of non-P450–mediated metabolic pathways that contribute to the absorption, distribution, metabolism, and excretion properties of current xenobiotics. Expand
Special Section on Emerging Novel Enzyme Pathways in Drug Metabolism — Commentary Cytochrome P 450 and Non – Cytochrome P 450 Oxidative Metabolism : Contributions to the Pharmacokinetics , Safety , and Efficacy of Xenobiotics
The drug-metabolizing enzymes that contribute to the metabolism or bioactivation of a drug play a crucial role in defining the absorption, distribution, metabolism, and excretion properties of thatExpand
Identification and Characterization of a Selective Human Carbonyl Reductase 1 Substrate
TLDR
In vitro investigations determined that 1 was slowly oxidized to 2 by cytochrome P450s 2D6, 3A4, and 3A5, followed by stereoselective reduction back to 1 and not its enantiomer, which was mediated by an NADPH-dependent cytosolic enzyme. Expand
Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
TLDR
The chiral aspects of warfarin reduction are described using an HPLC method that enabled the detection of individual warfarIn alcohol stereoisomers and a 9-fold higher velocity of warFarin reduction in the cytosol than in microsomes is found. Expand
Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes.
TLDR
CR1 was shown to be a tiaprofenic acid reductase in vitro and was also suggested to be the principal tiap rofenic Acid reduct enzyme in  vivo. Expand
Stereochemical considerations in pharmacokinetic processes of representative antineoplastic agents
TLDR
This review highlights the chemical transformations in pharmacokinetic processes of these chiral/prochiral compounds and discusses their different behaviors with metabolic enzymes or transporter proteins, to explicate the observed stereoselectivity intrinsically. Expand
Structural insights on the catalytic site protection of human carbonyl reductase 1 by glutathione.
TLDR
The crystal structure of hCBR1 in complex with GSH, in the absence of its substrates or inhibitors is presented, and it is found that the GSH molecule presents in a configuration quite different from that was previously reported when substrate is binding to hC BR1. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 251 REFERENCES
Human Carbonyl Reduction Pathways and a Strategy for Their Study In Vitro
TLDR
An overview of carbonyl‐reducing enzymes is provided, including some kinetic data for substrates and inhibitors, and an experimental strategy for the study of these enzymes in vitro is presented. Expand
Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro
TLDR
Evidence is provided for the first time evidence that seven specific carbonyl reducing enzymes participate in nabumetone metabolism. Expand
Role of type-1 11beta-hydroxysteroid dehydrogenase in detoxification processes.
TLDR
This review summarises the current knowledge of type-1 11beta-hydroxysteroid dehydrogenase and discusses possible substrate/inhibitor interactions that might impair either the physiological function of glucocorticoids or the detoxification of non-steroid carbonyl compounds. Expand
Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily
TLDR
It is clear that this area is, overall, quite unexplored, but carbonyl reducing enzymes located in the ER have proven very interesting, and the study of these enzymes could shed new light on the metabolism of several clinically used drugs or they could become an important target in connection with some diseases. Expand
Human carbonyl reductases.
TLDR
The present review summarizes the current knowledge on these enzymes with special emphasis on their role as a defence system against toxicants, as well as their possible physiological function and medical application and their possible association with cancer. Expand
Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology.
  • U. Oppermann
  • Chemistry, Medicine
  • Annual review of pharmacology and toxicology
  • 2007
TLDR
This review summarizes the current knowledge on structure and function relationships of the major human and mammalian carbonyl reductases identified and indicates protective roles toward xenobiotic carbonyls and quinones. Expand
Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase.
TLDR
The activity of hydrolases definitely brings a new look to the entire metabolism of ANTs in microsomal fraction, as formed aglycones undergo reduction and compete for the binding site with the main ANTs. Expand
Multiplicity of mammalian reductases for xenobiotic carbonyl compounds.
TLDR
Accumulating data on the human enzymes provide new insights into their roles in cellular and molecular reactions including xenobiotic metabolism, as well as suggesting their involvement in species-specific biological events and species differences in the metabolism of Xenobiotic carbonyl compounds. Expand
Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
TLDR
It was concluded that tolperisone undergoes P 450-dependent and P450-independent microsomal biotransformations to the same extent and on the basis of metabolites formed and indirect evidences of inhibition studies, a considerable involvement of aMicrosomal reductase is assumed. Expand
Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
TLDR
The structural models that are derived could serve as a useful tool for structure-guided drug design studies and for each enzyme and anthracycline pair provided the identification of key residues involved in the interactions. Expand
...
1
2
3
4
5
...